Systemic barriers to entry have led to severe inequities in cancer screening in the United States. For example, black women are more likely to be diagnosed with advanced breast cancer and are 41% more likely to die from the disease than white women. These issues are exacerbated by the 9.5 million missed screenings during the COVID-19 pandemic, which has led to an increase in late-stage cancer diagnoses, which are more costly and have a greater impact on the quality of care. life and outcomes as early stage diagnoses. .

Proactive Approach to Cancer Treatment - Precise Prevention

Founded in 2013 by Olufunmilayo (Funmi) Olopade, MD and Feyi Olopade Ayodele, CancerIQ's precision health platform, used by doctors in more than 180 locations across the country, makes it easy to determine the individual cancer risk of a patient based on family history, genetics, behavior and other factors, then connect them to the appropriate supply routes. These avenues range from MRIs, prophylactic surgeries and vaccinations to home screening kits, multi-cancer screening tests (MCED), lifestyle interventions and other services such as clinical trials, educational materials and social resources. CancerIQ is directly integrated into EMR workflows, so physicians in all healthcare settings have the latest genomics research, clinical guidelines, and life science innovations at their fingertips.

Read More: Best Daily News Update From White Hat Ranker

CancerIQ plans to use the recent funding round to grow its precision healthcare platform, strengthen its partnership ecosystem, and expand its network of healthcare systems. Following a recent round of key executive hires, the company also plans to hire 50 team members to meet the growing demand for more effective and innovative cancer prevention services.

"CancerIQ's vision is to end cancer as we know it by eliminating health inequalities and democratizing access to the latest advances in cancer screening and prevention," added Feyi Olopade Ayodele, co-founder and CEO of CancerIQ. “We started by making genetic testing more accessible and connecting patients to the right testing services at the right time. This latest round of funding will help CancerIQ reach more patients and connect with more innovations that promise to turn cancer from a deadly disease into a manageable condition.